Sacituzumab Govitecan, TROP-2 targeted antibody drug conjugate, is effective for the treatment of breast cancer, but its potential utility for the treatment of breast cancer brain metastasis and recurrent glioblastoma is unclear. Here, the authors present a window-of-opportunity phase 0 trial reporting the central nervous system penetrance and intracranial efficacy of Sacituzumab Govitecan.
- Henriette U. Balinda
- William J. Kelly
- Andrew J. Brenner
